Complete remission with immunotherapy: Case report of a patient with metastatic bladder cancer to the humerus

Bladder cancer is the sixth most common malignancy in the United States. Cisplatin combination regimens are first line therapy for patients with metastatic urothelial bladder cancer who are eligible candidates and no treatments have shown to improve outcome compared to chemotherapy for the past 20 y...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhakam, D., Young, P.R., Jain, M.K., Nassar, A., Copland, J.A., Tan, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036445/
https://www.ncbi.nlm.nih.gov/pubmed/32123665
http://dx.doi.org/10.1016/j.eucr.2020.101130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036445/
https://www.ncbi.nlm.nih.gov/pubmed/32123665
http://dx.doi.org/10.1016/j.eucr.2020.101130

Ejemplares similares